Mark T Bilodeau
Overview
Explore the profile of Mark T Bilodeau including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
625
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Perino S, Moreau B, Freda J, Cirello A, White B, Quinn J, et al.
Mol Cancer Ther
. 2020 Jun;
19(8):1613-1622.
PMID: 32499300
The PI3K pathway is considered a master regulator for cancer due to its frequent activation, making it an attractive target for pharmacologic intervention. While substantial efforts have been made to...
2.
Whalen K, White B, Quinn J, Kriksciukaite K, Alargova R, Au Yeung T, et al.
Mol Cancer Ther
. 2019 Oct;
18(11):1926-1936.
PMID: 31649014
Small cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma with a 95% mortality rate with no improvement to treatment in decades, and new therapies are desperately needed. PEN-221 is...
3.
White B, Whalen K, Kriksciukaite K, Alargova R, Au Yeung T, Bazinet P, et al.
J Med Chem
. 2019 Feb;
62(5):2708-2719.
PMID: 30735385
Somatostatin receptor 2 (SSTR2) is frequently overexpressed on several types of solid tumors, including neuroendocrine tumors and small-cell lung cancer. Peptide agonists of SSTR2 are rapidly internalized upon binding to...
4.
Beshore D, Di Marco C, Chang R, Greshock T, Ma L, Wittmann M, et al.
ACS Med Chem Lett
. 2018 Jul;
9(7):652-656.
PMID: 30034595
Identification of ligands that selectively activate the M muscarinic signaling pathway has been sought for decades to treat a range of neurological and cognitive disorders. Herein, we describe the optimization...
5.
Scott J, DeMong D, Greshock T, Basu K, Dai X, Harris J, et al.
J Med Chem
. 2017 Mar;
60(7):2983-2992.
PMID: 28245354
Leucine-rich repeat kinase 2 (LRRK2) is a large, multidomain protein which contains a kinase domain and GTPase domain among other regions. Individuals possessing gain of function mutations in the kinase...
6.
Wolkenberg S, Nolt M, Bilodeau M, Trotter B, Manley P, Kett N, et al.
Bioorg Med Chem Lett
. 2017 Jan;
27(4):1062-1069.
PMID: 28131713
Selective inhibition of Kv1.5, which underlies the ultra-rapid delayed rectifier current, I, has been pursued as a treatment for atrial fibrillation. Here we describe the discovery of MK-1832, a Kv1.5...
7.
Su H, Rickert K, Burlein C, Narayan K, Bukhtiyarova M, Hurzy D, et al.
Proc Natl Acad Sci U S A
. 2017 Jan;
114(3):E297-E306.
PMID: 28039433
Current therapies for chronic pain can have insufficient efficacy and lead to side effects, necessitating research of novel targets against pain. Although originally identified as an oncogene, Tropomyosin-related kinase A...
8.
Greshock T, Sanders J, Drolet R, Rajapakse H, Chang R, Kim B, et al.
Bioorg Med Chem Lett
. 2016 Apr;
26(11):2631-5.
PMID: 27106707
Familial Parkinson's disease cases have recently been associated with the leucine rich repeat kinase 2 (LRRK2) gene. It has been hypothesized that inhibition of the LRRK2 protein may have the...
9.
Stachel S, Zerbinatti C, Rudd M, Cosden M, Suon S, Nanda K, et al.
J Med Chem
. 2016 Mar;
59(7):3489-98.
PMID: 27011007
Herein, we describe the development of a functionally selective liver X receptor β (LXRβ) agonist series optimized for Emax selectivity, solubility, and physical properties to allow efficacy and safety studies...
10.
Brockman A, Oller H, Moreau B, Kriksciukaite K, Bilodeau M
J Med Chem
. 2015 Jan;
58(3):1420-5.
PMID: 25587854
Medicinal chemists have been encouraged in recent years to embrace high speed protein binding assays. These methods employ dialysis membranes in 96-well format or spin filters. Membrane-based methods do not...